ReviewFrontiers in endocrinology2021
Parathyroid Imaging: Past, Present, and Future.
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.Endocrine, metabolic & immune disorders drug targets · 2024Guideline
- First-line [European journal of nuclear medicine and molecular imaging · 2026Trial
- Article
- The Diagnostic Accuracy of [Diagnostics (Basel, Switzerland) · 2026Article
- Dual-isotope subtraction scintigraphy and SPECT-CT for preoperative localization of parathyroid adenomas.Clinical physiology and functional imaging · 2026Article
- Fine-needle-based localization techniques in parathyroid adenomas: a retrospective cohort study of histopathological safety and fibrosis patterns.Diagnostic pathology · 2026Article
- Software-Assisted Subtraction with Ultrasound-Correlated Interpretation Reduces Interpretive Ambiguity in Parathyroid Scintigraphy: A Preliminary Prospective Reporting Study.Diagnostics (Basel, Switzerland) · 2026Article
- Experience-informed interpretation of contrast-enhanced CT for parathyroid localization in Sestamibi-Negative Primary Hyperparathyroidism.Irish journal of medical science · 2026Article
- Preoperative imaging strategies to optimize surgical treatment in primary hyperparathyroidism (pHPT).BMC surgery · 2026Article
- Primary Hyperparathyroidism in Adults: Recent Developments in Diagnosis and Management.The Medical journal of Australia · 2026Review
- Primary hyperparathyroidism due to dual parathyroid adenomas: one orthotopic, one intrathymic in ectopic cervical thymus.JCEM case reports · 2026Article
- A comparison of three-dimensional-ring CZT and NaI(Tl) single-photon emission computed tomography systems usingQuantitative imaging in medicine and surgery · 2026Article
- Interventional Radiology in the Management of Parathyroid Disorders: Current Diagnostic and Therapeutic Approaches.Journal of clinical medicine · 2026Review
- Diagnostic accuracy of SPECT/CT in parathyroid adenoma detection: impact of radiopharmaceutical choice and quality control practices.EJNMMI reports · 2026Article
- Discordant sestamibi uptake in synchronous parathyroid carcinoma and adenoma.Endocrinology, diabetes & metabolism case reports · 2026Article
- MR Pulse Sequences for Parathyroid Adenoma Imaging Using [Nuclear medicine and molecular imaging · 2026Article
- Association Between Biochemical Parameters, Parathyroid Gland Morphometry, and Dual-Phase MIBI SPECT/CT Findings in Primary Hyperparathyroidism.Journal of clinical medicine · 2026Article
- Primary Hyperparathyroidism in the Pediatric Population: Surgical Considerations and Outcomes: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Diagnostic performance of 3T MRI preoperative localization of parathyroid adenomas in primary hyperparathyroidism.Frontiers in endocrinology · 2026Article
- Preoperative localization in primary hyperparathyroidism: a stepwise approach integrating PTH-FNA washout and second-lineFrontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of parathyroid imaging is to identify all sources of excess parathyroid hormone secretion pre-operatively. A variety of imaging approaches have been evaluated and utilized over the years for this purpose. Ultrasound relies solely on structural features and is without radiation, however is limited to superficial evaluation. 4DCT and 4DMRI provide enhancement characteristics in addition to structural features and dynamic enhancement has been investigated as a way to better distinguish parathyroid from adjacent structures. It is important to recognize that 4DCT provides valuable information however results in much higher radiation dose to the thyroid gland than the other available examinations, and therefore the optimal number of phases is an area of controversy. Single-photon scintigraphy with 99mTc-Sestamibi, or dual tracer 99mTc-pertechnetate and 99mTc-sestamibi with or without SPECT or SPECT/CT is part of the standard of care in many centers with availability and expertise in nuclear medicine. This molecular imaging approach detects cellular physiology such as mitochondria content found in parathyroid adenomas. Combining structural imaging such as CT or MRI with molecular imaging in a hybrid approach allows the ability to obtain robust structural and functional information in one examination. Hybrid PET/CT is widely available and provides improved imaging and quantification over SPECT or SPECT/CT. Emerging PET imaging techniques, such as 18F-Fluorocholine, have the exciting potential to reinvent parathyroid imaging. PET/MRI may be particularly well suited to parathyroid imaging, where available, because of the ability to perform dynamic contrast-enhanced imaging and co-registered 18F-Fluorocholine PET imaging simultaneously with low radiation dose to the thyroid. A targeted agent specific for a parathyroid tissue biomarker remains to be identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.